**Country Demographics**

- **World Bank Classification**: High income

- **Life expectancy at birth (in years):**
  - **Male**: 78
  - **Female**: 84

- **67%** of population living in urban areas

- **Premature mortality** due to CVD (death during 30-70 years of age) (% of deaths):
  - **Male**: 23.9%
  - **Female**: 10.9%

- **Prevalence of tobacco use age ≥15**
  - Global data: 36.1% (male) 6.8% (female)

- **Total mortality** due to CVD (% of deaths):
  - **Male**: 27.94%
  - **Female**: 36.25%

- **Male**: 63.8%
  - **Female**: 62.8%

- Percentage of adult population with raised total cholesterol (%):
  - **Global data**: 38.9%

- Percentage of adult population (age-standardized) who are insufficiently active (less than 150 minutes of moderate intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week):
  - **Male**: 37.5%
  - **Female**: 48.5%

- **Percentage of adults** (age-standardized estimate) who are insufficiently active (less than 150 minutes of moderate intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week):

- **Percentage of adult population with raised blood pressure** (SBP ≥140 mmHg or DBP ≥90 mmHg)
  - **Global data**: 24.1% (male) 20.1% (female)

- **Percentage of adolescents** (ages 11-17) who are insufficiently active (less than 60 minutes of moderate- to vigorous intensity physical activity daily):
  - **Male**: 78.1%
  - **Female**: 90.7%

- **Prevalence of diabetes in adults** (ages 20-79):
  - **Global data**: 9.1%
## Essential Medicines and Interventions

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors</td>
<td>In process/partially implemented</td>
</tr>
<tr>
<td>Metformin</td>
<td>In place</td>
</tr>
<tr>
<td>Aspirin</td>
<td>In place</td>
</tr>
<tr>
<td>Insulin</td>
<td>In place</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>In place</td>
</tr>
<tr>
<td>Warfarin</td>
<td>In place</td>
</tr>
<tr>
<td>Statins</td>
<td>In place</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>In place</td>
</tr>
</tbody>
</table>

## Clinical Practice and Guidelines

Locally-relevant (national or subnational level):

- Clinical tool to assess CVD risk: In process/partially implemented
- CVD prevention (within the last 5 years): In place
- Treatment of tobacco dependence: In place
- Detection and management of Atrial Fibrillation: In place

## Cardiovascular Disease Governance

A National strategy or plan that addresses:

- CVDs and their risk factors specifically: In process/partially implemented
- A national tobacco control plan: In place
- A national multisectoral coordination mechanism for tobacco control: In place
- A national surveillance system that includes CVDs and their risk factors: In process/partially implemented
- Policies that ensure screening of individuals at high risk of CVDs: In place

## Stakeholder action

- NGO advocacy for CVD policies and programmes: In place
- Active involvement of patients’ organizations in advocacy for CVD prevention and management: In place
- Involvement of civil society in the development and implementation of a national CVD prevention and control plan: In place
- Specific activities by cardiology professional associations aimed at 25% reduction in premature CVD mortality by 2025: In process/partially implemented
- Hypertension screening by businesses at workplaces: In place

Source References: Global Health Data Exchange; WHO Global Health Observatory data repository; WHO NCD Document repository; Country specific publications.

For more information, please email info@worldheart.org